SCHEMBL2499550

SCHEMBL2499550

Oc1cc(OCCCl)cc(OCCCl)c1

nearest known ligand 0.47

Predicted protein targets (top 4)

geneUniProtsupporting neighboursconfidence
CNR1 P21554 10/20 0.40
CNR2 P34972 10/20 0.40
CHRNB2 P17787 1/20 0.36
CHRNA4 P43681 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL972974 0.86 ALDH1A1 (0.44) CNR1CNR2CHRNB2CHRNA4
SCHEMBL3021743 0.79 CHRNB2 (0.61) CNR1CNR2CHRNB2CHRNA4
SCHEMBL16953317 0.79 CHRNB2 (0.33) CNR1CNR2CHRNB2CHRNA4
SCHEMBL974357 0.77 ALDH1A1 (0.44) CNR1CNR2
SCHEMBL9041156 0.76 ALDH1A1 (0.52) CHRNB2CHRNA4
SCHEMBL2004550 0.76 LTA4H (0.55) CNR1CNR2
SCHEMBL2767353 0.76 LTA4H (0.55)
SCHEMBL974832 0.76 TP53 (0.46) CNR1CNR2
SCHEMBL25797930 0.75 CNR1 (0.56) CNR1CNR2
SCHEMBL23374106 0.74 CNR1 (0.40) CNR1CNR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1751127-B1 NOVEL CYLOPENTA[B]BENZOFURAN DERIVATIVES AND THE UTILIZATION THEREOF INTERMED DISCOVERY GMBH (DE) 2012-07-11 EP disclosed
EP-1751127-B1 NOVEL CYLOPENTA[B]BENZOFURAN DERIVATIVES AND THE UTILIZATION THEREOF INTERMED DISCOVERY GMBH (DE) 2012-07-11 EP disclosed
US-8030347-B2 Cylopenta[b]benzofuran derivatives and the utilization thereof BAYER HEALTHCARE AG (DE) 2011-10-04 US disclosed
US-8030347-B2 Cylopenta[b]benzofuran derivatives and the utilization thereof BAYER HEALTHCARE AG (DE) 2011-10-04 US disclosed
US-8030347-B2 Cylopenta[b]benzofuran derivatives and the utilization thereof BAYER HEALTHCARE AG (DE) 2011-10-04 US disclosed
US-20090018113-A1 Novel Cylopenta[B]Benzofuran Derivatives and the Utilization Thereof BAYER HEALTHCARE AG (DE) 2009-01-15 US disclosed
US-20090018113-A1 Novel Cylopenta[B]Benzofuran Derivatives and the Utilization Thereof BAYER HEALTHCARE AG (DE) 2009-01-15 US disclosed
US-20090018113-A1 Novel Cylopenta[B]Benzofuran Derivatives and the Utilization Thereof BAYER HEALTHCARE AG (DE) 2009-01-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090018113-A1 Novel Cylopenta[B]Benzofuran Derivatives and the Utilization Thereof FKBP1A, FKBP2, FKBP1B CNR1 397/4885CNR2 315/4885CHRNB2 4404/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.